Guillermo Estivill-Torrús

Dr. Guillermo Estivill-Torrús

C-01 Group Lab & Neurosciences Unit of University Regional Hospital of Málaga, Instituto de Investigación Biomédica de Málaga (IBIMA Plataforma BIONAND), Málaga, Andalusia, Spain
orcid
Co-Leader of Neuroimmunology Group.Director of Group CTS643

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in Neurología
Verified
Journal Article
Open access
Pedro Jesús Serrano-CastroPedro Jesús Serrano-Castro
Pedro Jesús Serrano-Castro
Guillermo Estivill-TorrúsGuillermo Estivill-Torrús
Guillermo Estivill-Torrús
PCP. Cabezudo-García
P. Cabezudo-García
JRJ.A. Reyes-Bueno
J.A. Reyes-Bueno
NPN. Ciano Petersen
N. Ciano Petersen
FFF. Rodríguez de Fonseca
F. Rodríguez de Fonseca
SARS-CoV-2 was first detected in December 2019 in the Chinese city of Wuhan and has since spread across the world. At present, the virus has infected over 1.7 million people and caused over 100 000 deaths worldwide. Research is currently focused on understanding the acute infection and developing effective treatment strategies. In view of the magnitude of the epidemic, we conducted a speculative review of possible medium- and long-term neurological consequences of SARS-CoV-2 infection, with particular emphasis on neurodegenerative and neuropsychiatric diseases of neuroinflammatory origin, based on the available evidence on neurological symptoms of acute SARS-CoV-2 infection. We systematically reviewed the available evidence about the pathogenic mechanisms of SARS-CoV-2 infection, the immediate and lasting effects of the cytokine storm on the central nervous system, and the consequences of neuroinflammation for the central nervous system. SARS-CoV-2 is a neuroinvasive virus capable of triggering a cytokine storm, with persistent effects in specific populations. Although our hypothesis is highly speculative, the impact of SARS-CoV-2 infection on the onset and progression of neurodegenerative and neuropsychiatric diseases of neuroinflammatory origin should be regarded as the potential cause of a delayed pandemic that may have a major public health impact in the medium to long term. Cognitive and neuropsychological function should be closely monitored in COVID-19 survivors.

1 December 2007 in Pain
Verified
Journal Article
Closed access
MSMargarita Suardíaz
Margarita Suardíaz
Guillermo Estivill-TorrúsGuillermo Estivill-Torrús
Guillermo Estivill-Torrús
CGCarlos Goicoechea
Carlos Goicoechea
ABAinhoa Bilbao
Ainhoa Bilbao
FFFernando Rodríguez de Fonseca
Fernando Rodríguez de Fonseca
Oleoylethanolamide (OEA) is a natural fatty acid amide that mainly modulates feeding and energy homeostasis by binding to peroxisome proliferator-activated receptor-alpha (PPAR-alpha) [Rodríguez de Fonseca F, Navarro M, Gómez R, Escuredo L, Navas F, Fu J, et al. An anorexic lipid mediator regulated by feeding. Nature 2001;414:209-12; Fu J, Gaetani S, Oveisi F, Lo Verme J, Serrano A, Rodríguez de Fonseca F, et al. Oleoylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature 2003;425:90-3]. Additionally, it has been proposed that OEA could act via other receptors, including the vanilloid receptor (TRPV1) [Wang X, Miyares RL, Ahern GP. Oleoylethanolamide excites vagal sensory neurones, induces visceral pain and reduces short-term food intake in mice via capsaicin receptor TRPV1. J Physiol 2005;564:541-7.] or the GPR119 receptor [Overton HA, Babbs AJ, Doel SM, Fyfe MC, Gardner LS, Griffin G, et al. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab 2006;3:167-175], suggesting that OEA might subserve other physiological roles, including pain perception. We have evaluated the effect of OEA in two types of nociceptive responses evoked by visceral and inflammatory pain in rodents. Our results suggest that OEA has analgesic properties reducing the nociceptive responses produced by administration of acetic acid and formalin in two experimental animal models. Additional research was performed to investigate the mechanisms underlying this analgesic effect. To this end, we evaluated the actions of OEA in mice null for the PPAR-alpha receptor gene and compared its actions with those of PPAR-alpha receptor wild-type animal. We also compared the effect of MK-801 in order to evaluate the role of NMDA receptor in this analgesia. Our data showed that OEA reduced visceral and inflammatory responses through a PPAR-alpha-activation independent mechanism. Co-administration of subanalgesic doses of MK-801 and OEA produced an analgesic effect, suggesting the participation of glutamatergic transmission in the antinociceptive effect of OEA. This study represents a novel approach to the examination of the effectiveness of OEA in nociceptive responses and provides a framework for understanding its biological functions and endogenous targets in visceral and inflammatory pain.

26 July 2007 in Cerebral Cortex
Verified
Journal Article
Open access
PDF file
Guillermo Estivill-TorrúsGuillermo Estivill-Torrús
Guillermo Estivill-Torrús
PLPedro Llebrez-Zayas
Pedro Llebrez-Zayas
EMElisa Matas-Rico
Elisa Matas-Rico
LSLuis Javier Santín-Núñez
Luis Javier Santín-Núñez
CPCarmen Pedraza
Carmen Pedraza
FFFernando Rodríguez De Fonseca
Fernando Rodríguez De Fonseca
Lysophosphatidic acid (LPA) is a simple phospholipid with extracellular signaling properties mediated by specific G protein–coupled receptors. At least 2 LPA receptors, LPA1 and LPA2, are expressed in the developing brain, the former enriched in the neurogenic ventricular zone (VZ), suggesting a normal role in neurogenesis. Despite numerous studies reporting the effects of exogenous LPA using in vitro neural models, the first LPA1 loss-of-function mutants reported did not show gross cerebral cortical defects in the 50% that survived perinatal demise. Here, we report a role for LPA1 in cortical neural precursors resulting from analysis of a variant of a previously characterized LPA1-null mutant that arose spontaneously during colony expansion. These LPA1-null mice, termed maLPA1, exhibit almost complete perinatal viability and show a reduced VZ, altered neuronal markers, and increased cortical cell death that results in a loss of cortical layer cellularity in adults. These data support LPA1 function in normal cortical development and suggest that the presence of genetic modifiers of LPA1 influences cerebral cortical development.


1 October 2008 in Molecular and Cellular Neuroscience
Verified
Journal Article
Closed access
EMElisa Matas-Rico
Elisa Matas-Rico
BDBeatriz Garcia Diaz
Beatriz Garcia Diaz
PLPedro Llebrez-Zayas
Pedro Llebrez-Zayas
DLDiana Lopez-Barroso
Diana Lopez-Barroso
LSLuis Javier Santín-Núñez
Luis Javier Santín-Núñez
Guillermo Estivill-TorrúsGuillermo Estivill-Torrús
Guillermo Estivill-Torrús

15 July 2015 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
ESEva Santos-Nogueira
Eva Santos-Nogueira
CLClara López-Serrano
Clara López-Serrano
JHJoaquim Hernández
Joaquim Hernández
NLNatalia Lago
Natalia Lago
AAAlma M. Astudillo
Alma M. Astudillo
RLRuben Lopez-Vales
Ruben Lopez-Vales
Lysophosphatidic acid (LPA) is an extracellular lipid mediator involved in many physiological functions that signals through six known G-protein-coupled receptors (LPA1–LPA6). A wide range of LPA effects have been identified in the CNS, including neural progenitor cell physiology, astrocyte and microglia activation, neuronal cell death, axonal retraction, and development of neuropathic pain. However, little is known about the involvement of LPA in CNS pathologies. Herein, we demonstrate for the first time that LPA signaling via LPA1 contributes to secondary damage after spinal cord injury. LPA levels increase in the contused spinal cord parenchyma during the first 14 d. To model this potential contribution of LPA in the spinal cord, we injected LPA into the normal spinal cord, revealing that LPA induces microglia/macrophage activation and demyelination. Use of a selective LPA1 antagonist or mice lacking LPA1 linked receptor-mediated signaling to demyelination, which was in part mediated by microglia. Finally, we demonstrate that selective blockade of LPA1 after spinal cord injury results in reduced demyelination and improvement in locomotor recovery. Overall, these results support LPA–LPA1 signaling as a novel pathway that contributes to secondary damage after spinal cord contusion in mice and suggest that LPA1 antagonism might be useful for the treatment of acute spinal cord injury. SIGNIFICANCE STATEMENT This study reveals that LPA signaling via LPA receptor type 1 activation causes demyelination and functional deficits after spinal cord injury.